Skip to main content
News and Events

CIR New and Noteworthy

Information about CIR research, vaccines in the news, infectious diseases, and articles featuring CIR staff and faculty.

CIR Research and Articles featuring Faculty & Staff

Phase 3 Study Results for Tetravalent Dengue Vaccine Published in NEJM

Study results for a phase 3 trial titled: "Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults" were published on February 1, 2024 in the New England Journal of Medicine. CIR's Team FIRE conducted more than 30 trials for the development of the Butantan Dengue Vaccine (Butantan-DV) used in this study.  The study was conducted at 16 sites in Brazil and showed that Butantan-DV prevented symptomatic dengue virus 1 and dengue virus 2 through 2 years of follow up.

mosquitos in a feeding container

Learning more about mosquito transmission may help flavivirus vaccine development

An inpatient challenge study being conducted by CIR's team FIRE aims to learn more about how zika is transmitted between them and humans.

Photo of dengue rash on study volunteer

Infecting volunteers with dengue virus shows experimental drug’s promise

Study leader Anna Durbin discusses the power and limits of a provocative human challenge trial


Scientists deliberately gave women Zika — here’s why

Findings from a challenge study conducted by CIR's Team FIRE indicate that the two strains of Zika administered in the trial can be safely and effectively used to infect participants in a Zika vaccine trial.

scientist photo

How Human Challenge Trials Accelerate Vaccine Development

Vaccinated, intentionally infected, and sequestered in a hospital unit, volunteers help researchers fast-track promising vaccine candidates.

Vaccines in the News

poster of vaccine day 2024

JHVI Vaccine Day 2024

This year’s subject: Dengue: New Epidemics, New Vaccines will focus on recent Dengue outbreak trends and strides in vaccine development. 


FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus

The U.S. Food and Drug Administration approved Ixchiq, the first chikungunya vaccine. Ixchiq is approved for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus.

canva vaccines syringe and virus molecule

COVID-19 vaccination campaign saved 2.4 million lives, according to health economists

A working paper by researchers from the University of Southern California and Brown University analyzed the global impacts of COVID-19 vaccines.


First RSV Vaccine Approved in the US

The U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Events and Special Interest

photo of Rangos Building entrance

We've Moved!

The CIR's East Baltimore location has moved to the Rangos Building!

Effective May 28, 2024 our new address is:

855 N. Wolfe Street Suite 601

Baltimore, MD 21205


Beulah Sabundayo, Ellen McKenzie and Kawsar Talaat posing with poster of CIR founder Mary Lou Clements-Mann

Hampton House Farewell Celebration

The Hopkins community celebrates the rich history of Hampton House before its demolition to make way for a new state-of-the-art facility.

Read Journal Articles from our Faculty